Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

2025-12-29 03:40:40 ET

Thesis Overview

Precision BioSciences ( DTIL ) is developing gene therapies based on its ARCUS genome editing platform. Lead candidates are PBGENE-HBV, a potential hepatitis B virus (HBV) cure, as well as PBGENE-DMD, a differentiated in vivo gene editing therapy for Duchenne Muscular Dystrophy (DMD). DTIL has reported promising early data from its ongoing phase 1 trial of PBGENE-HBV, with more data expected in 2026 and a potential path to test-of-cure during 2026. According to company guidance, initial human data for PBGENE-DMD are expected in the 2nd half of 2026, and a BLA filing is planned for 2028 (however, an IND submission has not been announced yet, despite prior guidance of IND submission by the end of 2025)....

Read the full article on Seeking Alpha

For further details see: